在 Sodium Tetrahydroborate,Potassium Hydroxide体系中,用 四氢呋喃,水 用作溶剂,以40 G的收率获得阿伐那非 参考文献: A Process For The Preparation Of Avanafil And Its Novel Intermediates[fr] Procédé De Préparation D'Avanafil Et De Ses Nouveaux Intermédiaires 标题: A Process For The Preparation Of Avanafil And Its Novel Intermediates[fr] Procédé De Préparation D'Avanafil Et De Ses Nouveaux Intermédiaires 摘要:本发明涉及一种新型的化合物(II)及其在阿伐那非制备中的应用,[应在此处插入公式]其中r为-Oh,-Ci或-Or1,R1为c1到c3烷基.
专利号:WO-2022244943-A1 优先权日:2021-05-21 标题 :Method for predicting recurrence of lung cancer, and pharmaceutical composition for recurrence inhibition 发明人:LEE HO-YOUNG 权利人:SEOUL NAT UNIV R&DB FOUNDATION 摘要:The present invention relates to: a method for providing information necessary in predicting the recurrence of lung cancer; a pharmaceutical composition for inhibiting the recurrence of lung cancer; and the like. Since the present inventors have identified that in slow-cycling cancer cells responsible for lung cancer recurrence, RGS2 is significantly increased and ATF4 is reduced, it is expected that by measuring the level of expression or activity of RGS2 and ATF4, the likelihood of lung cancer recurrence can be easily and quickly predicted. In addition, since the present inventors have identified that the growth of slow-cycling cancer cells can be inhibited and the apoptosis thereof can be induced by eliminating the expression of RGS2 or blocking the protein synthesis inhibitory action of RGS2, the present invention is expected to be also variously usable in the drug development of lung cancer recurrence inhibiting therapeutic agents for inhibiting the expression or activity of RGS2.
专利号:WO-2024258389-A1 优先权日:2023-06-13 标 题 :Magnetic erector device 发明人:AÅžCI HALIL; ÇÖMLEKÇİ SELÇUK; YILDIRIM BAÅž FUNDA; SAVRAN MEHTAP; KÜÇÜKKEBABCI GÖRKEM; TANER RÜMEYSA 权利人:SUELEYMAN DEMIREL UENIVERSITESI IDARI VE MALI ISLER DAIRE BASKANLIGI GENEL SEKRETERLIK 摘要:The invention relates to a low-cost magnetic erector device that increases nitric oxide production via endothelial nitric oxide synthase from the endothelial layer, the innermost layer of the vascular structure, in the area where it is applied in vitro, without contact and without containing chemicals, increases the blood circulation of the tissue in the area where it is applied and also provides the possibility of repeated use and portable usability by means of its in vitro activity, contributes to vasodilatation in the area where it is applied with pulsed electromagnetic field (PEMF) and increases the synthesis of tissue growth factors such as vascular endothelial growth factor, does not cause painful stimuli and the power, frequency and duration of which can be adjusted.
专利号:EP-4630405-A1 优先权日:2022-12-06 标题 :Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
专利号:US-9751877-B2 优先权日:2012-09-21 标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders 发明人:PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT 权利人:PFIZER 摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:WO-2024123815-A1 优先权日:2022-12-06 标 题:Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
专利号:CA-2966800-A1 优先权日:2014-11-07 标 题:Synthesis of copanlisib and its dihydrochloride salt
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Avanafil. 2017 Aug 2. 42(3):113-114. doi: 10.18773/austprescr.2019.043. Epub 2019 May 13. 3: Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother. 2013 Oct;47(10):1312-20. doi: 10.1177/1060028013501989. Epub 2013 Sep 27. 9(9):1171-81. doi: 10.1080/17512433.2016.1195261. Epub 2016 Jun 13. 30(10):853-62. doi: 10.1007/s40266-013-0112-x. 9(9):1163-70. doi: 10.1080/17512433.2016.1212655. Epub 2016 Aug 2. 8:517-23. doi: 10.2147/VHRM.S26712. Epub 2012 Aug 29.
合成参考文献
参考文献:10.1111/j.1365-2125.2010.03828.x 摘要:Ückert S, Oelke M. Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Brit J Clinical Pharma. 2011 Jul 11;72(2):197–204. doi: 10.1111/j.1365-2125.2010.03828.x.